相关实验视频

Updated: Sep 10, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

更新的系统综述和元分析:循环等离子体激活剂抑制剂-1水平与与代谢功能障碍相关的脂肪性肝病之间的相关性

Qicong Li¹, Yuting Ruan¹, Yuqing Zhu¹

¹The First Clinical Medical College of Zhejiang Chinese Medical University, No 548, Binwen Road, Hangzhou, Zhejiang Province, China.

BMC gastroenterology

|August 21, 2025

概括

与代谢功能失调相关的脂肪性肝病 (MASLD) 患者的血原激活剂抑制剂-1 (PAI-1) 水平较高. 这种关联在地理上可能有所不同,这突显了MASLD研究的区域差异.

科学领域:

肝病学
代谢疾病
生物标志物

背景情况:

代谢功能障碍相关的脂肪性肝病 (MASLD),以前称为非酒精性脂肪性肝病,是一个全球性的健康问题.
目前对MASLD的诊断和治疗策略仍然有限.
血原激活剂抑制剂-1 (PAI-1) 参与MASLD的发病,可以作为诊断和治疗指标.

研究的目的:

进行更新的元分析,调查循环PAI-1水平与MASLD之间的关联.
综合评估PAI-1和MASLD在不同人群中的关系.

主要方法:

从七个数据库 (PubMed,Cochrane图书馆,EMBASE,CNKI,WANFANG,临床试验数据库,灰色文献数据库) 系统地检索研究.
使用RevMan 5. 3和Stata 12进行的元分析,结果报告为标准化平均差异 (SMD) 和95%的置信区间 (CI).
根据地理区域,年龄和BMI等因素进行了子组和元回归分析.

主要成果:

总共有23项研究被纳入了元分析.
与健康对照组相比,MASLD患者的循环PAI-1水平显著升高 (SMD=1. 44,95% CI [1. 06,1. 83]).
超回归表明地理区域是异质性的重要因素 (p < 0. 001),而BMI小组分析是不确定的.

结论:

被诊断为MASLD的患者在循环中的PAI-1水平显著增加.
PAI-1和MASLD之间的相关性可能受地理区域的影响.
结果为未来的MASLD研究提供了参考,强调需要考虑区域差异.

关键词:

综合分析与代谢功能障碍相关的脂肪性肝病非酒精性脂肪肝疾病血原激活剂抑制剂-1

更多相关视频

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

相关概念视频

Liver Physiology

Liver Physiology

The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...